Financial sustainability of payment models for office-based opioid treatment in outpatient clinics

被引:7
|
作者
Hodgkin, Dominic [1 ]
Horgan, Constance [1 ]
Bart, Gavin [2 ,3 ]
机构
[1] Brandeis Univ, Heller Sch Social Policy & Management, Inst Behav Hlth, Waltham, MA 02453 USA
[2] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA
[3] Hennepin Healthcare, Div Addict Med, Minneapolis, MN USA
关键词
Office-based opioid treatment; Buprenorphine; Medication treatment of opioid use disorder; Reimbursement; Payment models; Financial sustainability; Medicaid; USE DISORDER TREATMENT; PRIMARY-CARE; COLLABORATIVE CARE; BUPRENORPHINE; INDIVIDUALS; BARRIERS; IMPLEMENTATION; PHYSICIANS; DEPRESSION; ADDICTION;
D O I
10.1186/s13722-021-00253-7
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Office-Based Opioid Treatment (OBOT) is a delivery model which seeks to make medications for opioid use disorder (MOUD), particularly buprenorphine, widely available in general medical clinics and offices. Despite evidence supporting its effectiveness and cost-effectiveness, uptake of the OBOT model has been relatively slow. One important barrier to faster diffusion of OBOT may be the financial challenges facing clinics that could adopt it. Methods: We review key features and variants of the OBOT model, then discuss different approaches that have been used to fund it, and the findings from previous economic analyses of OBOT's impact on organizational finances. We conclude by discussing the implications of these analyses for the financial sustainability of the OBOT delivery model. Results: Like other novel services, OBOT poses challenges for providers due to its reliance on services which are `non-billable' in a fee-for-service environment. A variety of approaches exist for covering the non-billable costs, but which approaches are feasible depends on local payer policies. The scale of the challenges varies with clinic size, organizational affiliations and the policies of the state where the clinic operates. Small clinics in a purely fee-for-service environment may be particularly challenged in pursuing OBOT, given the need to fund a dedicated staff and extra administrative work. The current pandemic may pose both opportunities and challenges for the sustainability of OBOT, with expanded access to telemedicine, but also uncertainty about the durability of the expansion. Conclusion: The reimbursement environment for OBOT delivery varies widely around the US, and is evolving as Medicare (and possibly other payers) introduce alternative payment approaches. Clinics considering adoption of OBOT are well advised to thoroughly investigate these issues as they make their decision. In addition, payers will need to rethink how they pay for OBOT to make it sustainable.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Impact of Office-based Opioid Treatment on Emergency Visits and Hospitalization in Adolescents with Opioid Use Disorder
    Walker, Kim S.
    Bonny, Andrea E.
    McKnight, Erin R.
    Nahata, Milap C.
    [J]. JOURNAL OF PEDIATRICS, 2020, 219 : 236 - 242
  • [32] Intravenous Cancer Treatment Pricier in Hospital Outpatient than in Office-Based Setting
    不详
    [J]. AMERICAN HEALTH AND DRUG BENEFITS, 2014, 7 (04): : 239 - 240
  • [33] An Innovative Model for Implementing Office-Based Opioid Treatment in Community-Based Settings
    Brooks, E. Marshall
    Brasler, Paul
    [J]. JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED, 2020, 31 (03) : 1054 - 1060
  • [34] Office-based treatment of opioid dependence: Clinical challenges and opportunities for generalists.
    Sullivan, LE
    O'Connor, PG
    Schottenfeld, RS
    Fiellin, DA
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 : 169 - 169
  • [35] Cost-effectiveness of office-based buprenorphine treatment for opioid use disorder
    Qian, Gary
    Rao, Isabelle
    Humphreys, Keith
    Owens, Douglas K.
    Brandeau, Margaret L.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2023, 243
  • [36] Office-Based Maintenance Treatment of Opioid DependenceHow Does it Compare With Traditional Approaches?
    Erik W. Gunderson
    David A. Fiellin
    [J]. CNS Drugs, 2008, 22 : 99 - 111
  • [37] Definitive urine drug testing in office-based opioid treatment: a literature review
    Barthwell, Andrea G.
    Allgaier, Jeffrey
    Egli, Kenneth
    [J]. CRITICAL REVIEWS IN TOXICOLOGY, 2018, 48 (10) : 829 - 852
  • [38] Office-based practice and opioid-use disorders
    Clark, HW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (10): : 928 - 930
  • [39] Guideline development for office-based pharmacotherapies for opioid dependence
    Fiellin, DA
    Barthwell, AG
    [J]. JOURNAL OF ADDICTIVE DISEASES, 2003, 22 (04) : 109 - 120
  • [40] A collaborative opioid prescribing (CoOP) model linking opioid treatment programs with office-based buprenorphine providers
    Kenneth B Stoller
    [J]. Addiction Science & Clinical Practice, 10 (Suppl 1)